• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Intracranial Response of ALK Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery.

作者信息

Urbanska Edyta Maria, Santoni-Rugiu Eric, Melchior Linea Cecilie, Carlsen Jonathan Frederik, Sørensen Jens Benn

机构信息

Department of Oncology.

Department of Pathology, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark; Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.

出版信息

Clin Lung Cancer. 2021 Jul;22(4):e528-e532. doi: 10.1016/j.cllc.2020.04.012. Epub 2020 Jun 4.

DOI:10.1016/j.cllc.2020.04.012
PMID:32651064
Abstract
摘要

相似文献

1
Intracranial Response of ALK Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery.间变性淋巴瘤激酶（ALK）非小细胞肺癌在因药物性肝炎停用阿来替尼后对二线剂量递增的布加替尼的颅内反应，以及全脑放疗后继立体定向放射外科治疗后的复发情况
Clin Lung Cancer. 2021 Jul;22(4):e528-e532. doi: 10.1016/j.cllc.2020.04.012. Epub 2020 Jun 4.
2
ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.ALTA-2 研究：布加替尼治疗阿来替尼或塞瑞替尼治疗后进展的 ALK 阳性晚期非小细胞肺癌患者的 II 期研究。
Future Oncol. 2021 May;17(14):1709-1719. doi: 10.2217/fon-2020-1119. Epub 2021 Feb 11.
3
Revisiting a lower starting dose of alectinib in ALK-Positive non-small cell lung cancer.重新审视 ALK 阳性非小细胞肺癌中阿来替尼的较低起始剂量。
Cancer Treat Res Commun. 2021;27:100319. doi: 10.1016/j.ctarc.2021.100319. Epub 2021 Jan 23.
4
Alectinib shows CNS efficacy in ALK-positive NSCLC.阿来替尼在ALK阳性非小细胞肺癌中显示出中枢神经系统疗效。
Lancet Oncol. 2018 Oct;19(10):e520. doi: 10.1016/S1470-2045(18)30707-1. Epub 2018 Sep 21.
5
Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution.布加替尼治疗二线或后线 ALK 重排非小细胞肺癌：来自单中心的真实世界观察。
Anticancer Drugs. 2019 Aug;30(7):e0787. doi: 10.1097/CAD.0000000000000787.
6
Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.ALK 阳性非小细胞肺癌患者接受布加替尼早期准入项目治疗的实际治疗持续时间。
Future Oncol. 2020 May;16(15):1031-1041. doi: 10.2217/fon-2019-0849. Epub 2020 Apr 27.
7
Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.阿来替尼治疗间变性淋巴瘤激酶阳性转移性非小细胞肺癌：临床试验证据和脑转移治疗经验。
Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619831906. doi: 10.1177/1753466619831906.
8
Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.治疗间变性淋巴瘤激酶重排非小细胞肺癌脑转移
Oncol Res Treat. 2019;42(11):599-606. doi: 10.1159/000502755. Epub 2019 Sep 17.
9
First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALK Rearrangement: Real-World Data.一线阿来替尼对比布加替尼治疗伴有 ALK 重排的晚期非小细胞肺癌：真实世界数据。
Cancer Res Treat. 2024 Jan;56(1):61-69. doi: 10.4143/crt.2023.461. Epub 2023 Jul 14.
10
A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.对克唑替尼治疗失败的间变性淋巴瘤激酶融合的晚期非小细胞肺癌患者使用阿来替尼与塞瑞替尼的回顾性研究。
BMC Cancer. 2021 Mar 24;21(1):309. doi: 10.1186/s12885-021-08005-1.

引用本文的文献

1
Mechanisms of Resistance to ALK Inhibitors and Corresponding Treatment Strategies in Lung Cancer.肺癌中对ALK抑制剂的耐药机制及相应治疗策略
Int J Gen Med. 2025 Apr 15;18:2151-2171. doi: 10.2147/IJGM.S512395. eCollection 2025.
2
Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib.剂量递增的阿来替尼治疗转移性ALK阳性非小细胞肺癌且对标准剂量阿来替尼发生中枢神经系统复发患者的疗效和安全性
JTO Clin Res Rep. 2024 Feb 1;5(3):100645. doi: 10.1016/j.jtocrr.2024.100645. eCollection 2024 Mar.
3
The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors.
原发性和转移性脑肿瘤免疫检查点抑制剂免疫治疗的现状
Antibodies (Basel). 2023 Apr 4;12(2):27. doi: 10.3390/antib12020027.
4
Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.洛拉替尼治疗间变性淋巴瘤激酶阳性肺癌和中枢神经系统特异性复发患者的 II 期研究。
JCO Precis Oncol. 2022 May;6:e2100522. doi: 10.1200/PO.21.00522.
5
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.第三代表皮生长因子受体（EGFR）和间变性淋巴瘤激酶（ALK）抑制剂：耐药机制与处理
Nat Rev Clin Oncol. 2022 Aug;19(8):499-514. doi: 10.1038/s41571-022-00639-9. Epub 2022 May 9.